Oncology

Dr. Ruth J. Simmons' tribute to her sister at Texas Southern University is more than a donation; it's a strategic model for tackling deep-seated health disparities.

For many rural families, a child's heart defect was a death sentence. Now, a coal company's ambitious CSR program is rewriting their future, one tiny heart at a time.

AbbVie's latest dividend increase isn't just good news for investors; it's a window into the pharma giant's strategy for navigating future challenges.

An independent study reveals a Quebec-based platform dramatically improves patient outcomes and slashes clinical workload. Is this the new OS for healthcare?

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

A new alliance aims to get an FDA-cleared device for a painful chemo side effect into patients' hands, tackling the hidden barriers of healthcare logistics.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

A young fan’s World Cup dream comes true, revealing a multi-million dollar corporate strategy that turns sports sponsorship into tangible results.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A court ruling clears the way for Curium's targeted cancer drug, promising new hope for patients and shaking up the multi-billion-dollar radiopharmaceutical market.

Asimov's AI-driven synthetic biology platform partners with McGill's Goodman Cancer Institute, aiming to break the manufacturing bottleneck for complex drugs.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

Early trial data for a novel antibody-drug conjugate shows a 32% response rate in a hard-to-treat patient group, signaling a potential new front in precision oncology.

As Oncoinvent accelerates its Phase 2 trial, a novel alpha-emitter therapy shows promise against a deadly cancer, signaling progress in radiopharmaceuticals.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

AB Science has secured a US patent until 2042 for masitinib, a targeted therapy for advanced prostate cancer, offering new hope where few options exist.

With $4.3M in seed funding and a roster of industry titans, Acurion is poised to commercialize its OncoGaze™ AI, aiming to make precision oncology faster.